We are excited to collaborate with Biogen on litifilimab,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “Royalty Pharma offers tailored, win-win funding solutions for ...

Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...

Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D) funding of up ...

Seven rheumatology researchers have authored a paper questioning the utility of the 2024 National Academies’ broad definition of long COVID.

Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs.

Fortunately, we are making some progress as organizations such as the Partnership for Advancing Clinical Trials (PACT) ...

The Conference Forum has announced the 9th annual Patients as Partners® Europe event, scheduled for May 20-21, 2025, at the Royal National Hotel ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Service Income and Other Operating Revenue for the year ending 31-Mar-2024.For the quarter ended 30-09-2024, ...